Method to enhance immunogenicity of live typhoid vaccines and carriers
US11254713B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 1, 2018 |
| Grant date | Feb 22, 2022 |
| Priority date | — |
| Expiry date | May 18, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain embodiments, a recombinant attenuated derivative of a pathogenic Salmonella enterica serovar typhi cell is provided, (a) wherein one or more genes encoding subunits of a stg operon (Salmonella typhi Δstg) are inactivated or deleted resulting in a decrease of Stg adhesin/fimbriae production as compared to genes encoding a wild-type Stg operon (stgABCC′D), and/or (b) the cell comprises a nucleic acid encoding at least one of a gene encoding a subunit of a long polar fimbriae (Lpf) of S. enterica serovar Typhimurium protein. In certain embodiments, vaccines and compositions, and methods of use of the recombinant attenuated derivative of a pathogenic Salmonella enterica serovar typhi cell are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.